+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting ESAs Market - Global Forecast 2026-2032- Product Image
Long-acting ESAs Market - Global Forecast 2026-2032- Product Image
Sale

Long-acting ESAs Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118180
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Long-acting ESAs Market is projected to reach USD 257.14 Million in 2026. It is expected to continue growing at a CAGR of 6.13%, reaching USD 369.12 Million by 2032.

Long-Acting ESAs: Clinical Role and Strategic Context

Long-acting erythropoiesis-stimulating agents (ESAs) are medicines designed to stimulate red-blood-cell production over extended dosing intervals. Their established clinical role is the management of selected forms of anemia, particularly anemia associated with chronic kidney disease and certain cancer-treatment pathways, subject to product labeling and local clinical guidance. Their value proposition centers on reducing administration frequency, supporting continuity of care, and enabling more structured monitoring of hemoglobin and iron status. Use remains dependent on individualized risk assessment because ESA therapy can be associated with hypertension, thromboembolic events, and other safety concerns when used inappropriately or when hemoglobin targets are exceeded.

Care Pathways Are Shifting Toward Individualized, Lower-Burden Anemia Management

The long-acting ESA landscape is being shaped by a broader shift toward patient-centered treatment pathways. Clinicians are balancing dosing convenience with conservative hemoglobin management, iron optimization, transfusion avoidance, and cardiovascular risk mitigation. Dialysis delivery models, outpatient oncology services, home-based care, and integrated chronic-disease programs increasingly influence how injectable therapies are selected and administered. Biosimilar adoption, procurement discipline, pharmacovigilance, and continuity of supply are also important structural considerations, while evolving alternatives for anemia management encourage providers to reassess treatment sequencing rather than rely on a single therapeutic class.

Artificial Intelligence Is Improving Monitoring, Triage, and Treatment Governance

Artificial intelligence can support long-acting ESA care by identifying patients at risk of hemoglobin instability, flagging missed administrations, and integrating laboratory trends with renal function, iron indices, inflammation, and comorbidity data. Predictive tools may help clinicians prioritize follow-up and detect potential under-response, although outputs require clinical validation and human oversight. In health-system operations, AI can assist inventory planning, appointment coordination, adverse-event surveillance, and documentation review. Responsible implementation requires representative data, transparent decision logic, privacy protections, cybersecurity controls, and clear accountability so that algorithmic recommendations do not replace clinician judgment or approved prescribing information.

Regional Priorities Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America emphasizes evidence-based utilization, safety monitoring, reimbursement controls, and integration with specialized kidney and oncology services. Europe places strong weight on health-technology assessment, biosimilar competition, coordinated procurement, and harmonized safety governance, while national implementation still varies. Latin America is characterized by differing public and private access pathways, uneven diagnostic capacity, and the importance of reliable distribution and affordability. The Middle East combines advanced specialist centers with varied reimbursement and regulatory environments across countries. Africa’s priorities include diagnosis, treatment continuity, supply reliability, and workforce capacity, particularly where renal-care infrastructure is constrained. Asia-Pacific spans highly developed systems and rapidly expanding healthcare capacity, making local regulatory requirements, dialysis access, manufacturing resilience, and affordability central considerations.

ASEAN, BRICS, the European Union, G7, GCC, and NATO Reflect Distinct System Priorities

ASEAN members differ substantially in reimbursement structures, regulatory maturity, and access to nephrology and oncology services, creating a need for adaptable implementation models. BRICS economies combine large patient populations with varied public procurement systems, domestic production capabilities, and unequal access across urban and rural settings. The European Union benefits from shared regulatory principles while retaining national differences in reimbursement, tendering, and clinical practice. G7 health systems generally have mature specialist infrastructure and extensive safety-monitoring capabilities, but continue to focus on affordability and service efficiency. GCC countries often possess well-resourced tertiary centers while addressing workforce development and regional care coordination. NATO membership is not a healthcare market category, yet its members’ health systems may share concerns about supply-chain resilience, emergency preparedness, and continuity of essential medicines.

Country-Level Conditions Shape Adoption, Access, and Clinical Practice

Australia combines established renal services with geographically dispersed populations, making treatment continuity and specialist access important. Brazil’s priorities include public-system procurement, regional disparities, and consistent anemia monitoring. Canada must address large distances, provincial variation, and coordination between dialysis and hospital services. China is influenced by healthcare reform, local procurement, domestic manufacturing, and expanding chronic-kidney-disease management. France, Germany, Italy, and Spain operate within European regulatory structures but differ in reimbursement, tendering, and care delivery. India faces substantial variation in affordability, diagnostics, and specialist availability alongside growing demand for renal care. Japan emphasizes structured clinical management, an aging population, and system efficiency. Mexico must navigate public-sector fragmentation and unequal access. Russia’s considerations include supply continuity, domestic production, and geographic coverage. South Korea combines advanced hospital capacity with a strong focus on technology-enabled care. The United Kingdom emphasizes national guidance, procurement, and integrated care pathways. The United States has extensive specialist infrastructure but complex payer rules, site-of-care differences, and close scrutiny of safety and cost.

Industry Leaders Should Prioritize Safety, Continuity, Evidence, and Operational Fit

Leaders should align product positioning and clinical education with approved indications, conservative hemoglobin management, iron assessment, and transparent communication of risks. They should strengthen real-world evidence on adherence, transfusion avoidance, patient-reported burden, and outcomes across renal and oncology settings without overstating comparative benefits. Supply-chain planning should include qualified manufacturing capacity, cold-chain controls where applicable, shortage-response procedures, and dependable distribution to underserved locations. Partnerships with dialysis providers, hospitals, payers, and patient groups can improve implementation, while digital tools should be introduced through validated workflows with human oversight. Regional strategies should account for tendering, reimbursement, biosimilar policy, local evidence requirements, and differences in healthcare infrastructure.

Methodology: Evidence-Based Synthesis of Clinical, Regulatory, and System-Level Factors

This executive summary uses the supplied market scope-long-acting ESAs-and organizes evidence around established clinical use, treatment safety, healthcare delivery, access conditions, digital transformation, and regional system characteristics. The assessment is qualitative and avoids market estimates, market sizing, market shares, and forecasts. It distinguishes broad, documented healthcare-system patterns from country-level implementation considerations and does not infer product performance beyond approved clinical evidence. A rigorous full study would triangulate clinical guidelines, regulatory documents, peer-reviewed literature, health-technology assessments, procurement policies, pharmacovigilance sources, and structured expert input, while separately validating each jurisdiction’s reimbursement and prescribing environment.

The Strategic Outlook Centers on Responsible, Resilient, Patient-Centered Use

Long-acting ESAs remain relevant where extended dosing can support anemia management within carefully governed clinical pathways. Their future role will depend less on convenience alone and more on demonstrable safety, appropriate patient selection, reliable monitoring, affordability, and integration with iron management and emerging treatment options. Regional and country differences require localized access and implementation strategies, while AI can add value only when validated, secure, and clinically supervised. Organizations that combine evidence-led practice with resilient supply, clear risk governance, and patient-centered service design will be better positioned to support consistent outcomes across diverse healthcare systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Long-acting ESAs Market, by Product Type
7.1. Introduction
7.2. Biosimilar
7.2.1. Darbepoetin Alfa
7.2.2. Epoetin Beta
7.3. Originator
7.3.1. Darbepoetin Alfa
7.3.2. Epoetin Beta
8. Long-acting ESAs Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous
9. Long-acting ESAs Market, by Drug Adminstration
9.1. Introduction
9.2. Hyperglycosylated ESA
9.3. PEGylated ESA
10. Long-acting ESAs Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Ambulatory Care Clinics
10.2.2. Specialty Clinics
10.3. Home Care
10.3.1. Nurse Assisted Administration
10.3.2. Self Administration
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Long-acting ESAs Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Long-acting ESAs Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Long-acting ESAs Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Amgen Inc.
15.2. Aurobindo Pharma Ltd.
15.3. Biocon Biologics Ltd.
15.4. Boehringer Ingelheim
15.5. Cipla Ltd.
15.6. Dr. Reddy's Laboratories Ltd.
15.7. Intas Pharmaceuticals Ltd.
15.8. Johnson & Johnson
15.9. Mylan N.V.
15.10. Novartis AG
15.11. Pfizer Inc.
15.12. Roche Holding AG
15.13. Sun Pharmaceutical Industries Ltd.
15.14. Teva Pharmaceutical Industries Ltd.
15.15. Viatris Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Long-acting ESAs Market, Years Considered for the Study
FIGURE 2. Global Long-acting ESAs Market, Research Design
FIGURE 3. Global Long-acting ESAs Market, Research Framework
FIGURE 4. Global Long-acting ESAs Market, Data Triangulation
FIGURE 5. Global Long-acting ESAs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Long-acting ESAs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Long-acting ESAs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Long-acting ESAs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Long-acting ESAs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Long-acting ESAs Market Size, by Drug Adminstration, 2025 vs 2032 (%)
FIGURE 11. Global Long-acting ESAs Market Size, by Drug Adminstration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Long-acting ESAs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Long-acting ESAs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Long-acting ESAs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Long-acting ESAs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Long-acting ESAs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Long-acting ESAs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Long-acting ESAs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Long-acting ESAs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Long-acting ESAs Market Segmentation & Coverage
TABLE 2. Global Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biosimilar Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Darbepoetin Alfa Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Darbepoetin Alfa Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Darbepoetin Alfa Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Epoetin Beta Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Epoetin Beta Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Epoetin Beta Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Originator Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Originator Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Originator Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Darbepoetin Alfa Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Darbepoetin Alfa Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Darbepoetin Alfa Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Epoetin Beta Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Epoetin Beta Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Epoetin Beta Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 30. Global Hyperglycosylated ESA Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Hyperglycosylated ESA Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Hyperglycosylated ESA Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global PEGylated ESA Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global PEGylated ESA Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global PEGylated ESA Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 37. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Ambulatory Care Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Ambulatory Care Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Ambulatory Care Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Nurse Assisted Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Nurse Assisted Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Nurse Assisted Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 75. North America Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. North America Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 77. North America Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 78. North America Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 79. North America Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 80. North America Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 81. North America Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 82. North America Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 83. North America Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 84. North America Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 85. Latin America Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Latin America Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Latin America Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 88. Latin America Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 89. Latin America Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Latin America Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 91. Latin America Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Latin America Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 93. Latin America Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 94. Latin America Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 95. Europe Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Europe Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 97. Europe Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 98. Europe Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 99. Europe Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. Europe Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 101. Europe Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Europe Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 103. Europe Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 104. Europe Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 105. Middle East Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Middle East Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Middle East Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 108. Middle East Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 109. Middle East Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. Middle East Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 111. Middle East Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. Middle East Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 113. Middle East Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 114. Middle East Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 115. Africa Long-acting ESAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Africa Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. Africa Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 118. Africa Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 119. Africa Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. Africa Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 121. Africa Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Africa Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 123. Africa Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 124. Africa Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 125. Global Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 128. ASEAN Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 129. ASEAN Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 130. ASEAN Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. ASEAN Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 132. ASEAN Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. ASEAN Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 134. ASEAN Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 135. ASEAN Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 136. GCC Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. GCC Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. GCC Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 139. GCC Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 140. GCC Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. GCC Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 142. GCC Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. GCC Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 144. GCC Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 145. GCC Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 146. European Union Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. European Union Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. European Union Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 149. European Union Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 150. European Union Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. European Union Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 152. European Union Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. European Union Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 154. European Union Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 155. European Union Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 156. BRICS Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. BRICS Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 158. BRICS Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 159. BRICS Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 160. BRICS Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. BRICS Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 162. BRICS Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. BRICS Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 164. BRICS Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 165. BRICS Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 166. G7 Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. G7 Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. G7 Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 169. G7 Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 170. G7 Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. G7 Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 172. G7 Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. G7 Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 174. G7 Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 175. G7 Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 176. NATO Long-acting ESAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. NATO Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 178. NATO Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 179. NATO Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 180. NATO Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. NATO Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 182. NATO Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. NATO Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 184. NATO Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 185. NATO Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 186. Global Long-acting ESAs Market Size, by Country, 2017-2032 (USD Million)
TABLE 187. United States Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 188. United States Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. United States Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 190. United States Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 191. United States Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 192. United States Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 193. United States Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. United States Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 195. United States Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 196. United States Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 197. Canada Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 198. Canada Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 199. Canada Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 200. Canada Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 201. Canada Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 202. Canada Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 203. Canada Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Canada Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 205. Canada Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 206. Canada Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 207. Mexico Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 208. Mexico Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 209. Mexico Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 210. Mexico Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 211. Mexico Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. Mexico Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 213. Mexico Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. Mexico Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 215. Mexico Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 216. Mexico Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 217. Brazil Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 218. Brazil Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. Brazil Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 220. Brazil Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 221. Brazil Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. Brazil Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 223. Brazil Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Brazil Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 225. Brazil Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 226. Brazil Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 227. United Kingdom Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 228. United Kingdom Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. United Kingdom Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 230. United Kingdom Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 231. United Kingdom Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. United Kingdom Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 233. United Kingdom Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. United Kingdom Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 235. United Kingdom Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 236. United Kingdom Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 237. Germany Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 238. Germany Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 239. Germany Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 240. Germany Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 241. Germany Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. Germany Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 243. Germany Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Germany Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 245. Germany Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 246. Germany Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 247. France Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 248. France Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. France Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 250. France Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 251. France Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. France Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 253. France Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. France Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 255. France Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 256. France Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 257. Russia Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 258. Russia Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 259. Russia Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 260. Russia Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 261. Russia Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. Russia Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 263. Russia Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. Russia Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 265. Russia Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 266. Russia Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 267. Italy Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 268. Italy Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Italy Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 270. Italy Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 271. Italy Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. Italy Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 273. Italy Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Italy Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 275. Italy Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 276. Italy Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 277. Spain Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 278. Spain Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 279. Spain Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 280. Spain Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 281. Spain Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 282. Spain Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 283. Spain Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. Spain Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 285. Spain Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 286. Spain Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 287. China Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 288. China Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 289. China Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 290. China Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 291. China Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 292. China Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 293. China Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. China Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 295. China Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 296. China Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 297. India Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 298. India Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 299. India Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 300. India Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 301. India Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 302. India Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 303. India Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 304. India Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 305. India Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 306. India Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 307. Japan Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 308. Japan Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 309. Japan Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 310. Japan Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 311. Japan Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. Japan Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 313. Japan Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Japan Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 315. Japan Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 316. Japan Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 317. Australia Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 318. Australia Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 319. Australia Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 320. Australia Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 321. Australia Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 322. Australia Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 323. Australia Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 324. Australia Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 325. Australia Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 326. Australia Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 327. South Korea Long-acting ESAs Market Size, 2017-2032 (USD Million)
TABLE 328. South Korea Long-acting ESAs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 329. South Korea Long-acting ESAs Market Size, by Biosimilar, 2017-2032 (USD Million)
TABLE 330. South Korea Long-acting ESAs Market Size, by Originator, 2017-2032 (USD Million)
TABLE 331. South Korea Long-acting ESAs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 332. South Korea Long-acting ESAs Market Size, by Drug Adminstration, 2017-2032 (USD Million)
TABLE 333. South Korea Long-acting ESAs Market Size, by End User, 2017-2032 (USD Million)
TABLE 334. South Korea Long-acting ESAs Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 335. South Korea Long-acting ESAs Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 336. South Korea Long-acting ESAs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 337. Global Long-acting ESAs Market Share, by Key Player, 2025
TABLE 338. Global Long-acting ESAs Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Biocon Biologics Ltd.
  • Boehringer Ingelheim
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Parenteral PrEP Market - Global Forecast 2026-2032 - Product Image

Parenteral PrEP Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Bioengineered Protein Drugs Market - Global Forecast 2026-2032 - Product Image

Bioengineered Protein Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Antibody Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Antibody Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Ryzneuta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Ryzneuta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Therapeutic Proteins Market Report 2026 - Product Image

Therapeutic Proteins Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.